Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-09-16 Sale | 2024-09-17 5:21 pm | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 37,000 | $36.23 | $1,340,597 | 247,526 (Indirect Direct) | View |
2024-09-16 Sale | 2024-09-17 4:08 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 192 | $36.21 | $6,952 | 38,141 (Direct) | View |
2024-09-03 Sale | 2024-09-04 4:07 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 550 | $39.49 | $21,720 | 38,333 (Direct) | View |
2024-06-21 Sale | 2024-06-21 7:34 pm | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 37,000 | $39.24 | $1,451,835 | 302,371 (Indirect Direct) | View |
2024-05-08 Sale | 2024-05-09 5:15 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 78,907 | $42.35 | $3,341,848 | 1,224,605 (Direct) | View |
2024-04-08 Sale | 2024-04-09 4:25 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $54.17 | $3,743,605 | 1,153,263 (Direct) | View |
2024-04-01 Sale | 2024-04-02 4:06 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 4,000 | $58.66 | $234,640 | 407,473 (Indirect Direct) | View |
2024-03-19 Sale | 2024-03-20 5:18 pm | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 18,681 | $57.18 | $1,068,161 | 337,871 (Indirect Direct) | View |
2024-03-18 Sale | 2024-03-19 4:03 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 9,913 | $56.9 | $564,050 | 54,693 (Direct) | View |
2024-03-15 Sale | 2024-03-18 4:19 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 184 | $56.46 | $10,389 | 38,883 (Direct) | View |
2024-03-13 Sale | 2024-03-14 4:17 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 11,220 | $57.56 | $645,838 | 56,287 (Direct) | View |
2024-03-08 Sale | 2024-03-11 4:08 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $62.19 | $4,297,549 | 1,222,370 (Direct) | View |
2024-03-01 Sale | 2024-03-05 4:07 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 250,000 | $64.11 | $16,028,706 | 2,219,608 (Indirect Direct) | View |
2024-03-01 Sale | 2024-03-05 4:04 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 6,000 | $63.22 | $379,340 | 411,473 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 5:06 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 781 | $67.77 | $52,926 | 194,095 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 5:05 pm | Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer | 1,148 | $67.77 | $77,796 | 92,453 (Direct) | View |
2024-02-12 Sale | 2024-02-13 4:59 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 1,431 | $67.77 | $96,974 | 149,570 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 4:49 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 3,962 | $67.77 | $268,492 | 2,035,230 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 4:43 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 1,148 | $67.77 | $77,796 | 1,115,983 (Direct) | View |
2024-02-12 Sale | 2024-02-13 4:38 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 597 | $67.77 | $40,457 | 64,606 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:38 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 906 | $64.14 | $58,109 | 194,876 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 4:36 pm | Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer | 906 | $64.14 | $58,109 | 93,601 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:34 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 906 | $64.14 | $58,109 | 151,001 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 4:31 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 835 | $64.14 | $53,555 | 67,507 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:28 pm | Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer | 1,250 | $65.12 | $81,402 | 46,387 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:26 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 2,843 | $64.14 | $182,345 | 2,039,192 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 4:23 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 1,250 | $65.22 | $81,524 | 57,208 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:21 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 874 | $64.14 | $56,057 | 1,117,131 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:18 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 367 | $64.14 | $23,539 | 65,203 (Direct) | View |
2024-01-23 Sale | 2024-01-24 4:06 pm | Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer | 4,286 | $63.69 | $272,975 | 47,637 (Direct) | View |
2024-01-23 Sale | 2024-01-24 4:03 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 7,378 | $63.69 | $469,905 | 58,458 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-11-01 Other | 2024-11-01 6:43 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 182,146 | $0 | 2,035,230 (Indirect) | View |
2024-09-27 Gift | 2024-09-30 4:15 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 10,569 | $0 | 197,857 (Indirect) | View |
2024-09-23 Exercise | 2024-09-24 4:20 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 4,600 | $13.19 | 252,126 (Direct) | View |
2024-09-23 Exercise | 2024-09-24 4:20 pm | N/A 2028-12-31 | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 4,600 | $0 | 252,126 (Direct) | View |
2024-08-12 Exercise | 2024-08-13 4:13 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 5,201 | $13.85 | 75,194 (Direct) | View |
2024-08-12 Exercise | 2024-08-13 4:13 pm | N/A 2029-02-27 | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 5,201 | $0 | 75,194 (Direct) | View |
2024-06-28 Exercise | 2024-07-01 4:02 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 900 | $13.19 | 307,871 (Direct) | View |
2024-06-28 Exercise | 2024-07-01 4:02 pm | N/A 2028-12-31 | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 900 | $0 | 307,871 (Direct) | View |
2024-05-20 Exercise | 2024-05-21 4:03 pm | N/A 2026-02-06 | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 24,500 | $0 | 1,153,263 (Direct) | View |
2024-05-20 Exercise | 2024-05-21 4:03 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 24,500 | $3.76 | 1,153,263 (Direct) | View |
2024-05-08 Exercise | 2024-05-09 5:15 pm | N/A 2027-08-22 | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 78,907 | $0 | 1,224,605 (Direct) | View |
2024-05-08 Exercise | 2024-05-09 5:15 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 78,907 | $4.31 | 1,224,605 (Direct) | View |
2024-04-18 Gift | 2024-04-19 7:27 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 14,164 | $0 | 149,570 (Direct) | View |
2024-04-12 Exercise | 2024-04-15 4:09 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 1,500 | $13.19 | 344,871 (Direct) | View |
2024-04-12 Exercise | 2024-04-15 4:09 pm | N/A 2028-12-31 | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 1,500 | $0 | 344,871 (Direct) | View |
2024-04-08 Exercise | 2024-04-09 4:25 pm | N/A 2026-02-07 | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $0 | 1,153,263 (Direct) | View |
2024-04-08 Exercise | 2024-04-09 4:25 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $3.76 | 1,153,263 (Direct) | View |
2024-04-01 Exercise | 2024-04-02 4:06 pm | N/A 2027-10-18 | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 4,000 | $0 | 407,473 (Direct) | View |
2024-04-01 Exercise | 2024-04-02 4:06 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 4,000 | $10.03 | 407,473 (Direct) | View |
2024-03-08 Exercise | 2024-03-11 4:08 pm | N/A 2026-02-07 | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $0 | 1,222,370 (Direct) | View |
2024-03-08 Exercise | 2024-03-11 4:08 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $3.67 | 1,222,370 (Direct) | View |
2024-03-06 Exercise | 2024-03-08 07:45 am | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 3,762 | $13.85 | 197,857 (Direct) | View |
2024-03-06 Exercise | 2024-03-08 07:45 am | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 3,762 | $0 | 197,857 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:07 pm | N/A 2026-02-06 | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 250,000 | $0 | 2,219,608 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:07 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 50,000 | $3.76 | 2,219,608 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:07 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 200,000 | $4.31 | 2,219,608 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:04 pm | N/A 2027-10-18 | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 6,000 | $0 | 411,473 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:04 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 6,000 | $10.03 | 411,473 (Direct) | View |